FDA Commissioner Marty Makary Resigns Following Industry Pressure

Marty Makary, Commissioner of the FDA, is stepping down following a turbulent tenure defined by senior leadership attrition, inconsistent regulatory decision-making, and sustained pushback from pharmaceutical stakeholders.1 His exit comes after escalating criticism from drug manufacturers, anti-abortion groups, and vaping industry lobbyists.2

Kyle Diamantas, the agency's current Chief of Foods and a Trump-aligned attorney, will assume the role of acting commissioner as the White House initiates a search for a permanent, Senate-confirmed successor.2

Why Is Makary Resigning?

Makary, a surgical oncologist and health researcher, rose to political prominence as a critic of pandemic-era health mandates.2 However, his transition to regulatory leadership was fraught with administrative challenges. Under his leadership, the FDA experienced significant turnover, as many senior career officials resigned, retired, or were forced out within the first year of the administration.2

This revolving door of leadership, combined with allegations that scientific principles were frequently overridden by political interests, specifically those of Health and Human Services Secretary Robert F. Kennedy Jr., reportedly lowered staff morale and created a climate of dysfunction and frustration.2

How Will Makary’s Resignation Impact the Pharmaceutical Sector?

Makary’s impending departure highlights a period of regulatory unpredictability. While Makary promoted initiatives to streamline drug reviews, including the integration of artificial intelligence and dropping certain study requirements, these efforts were sometimes eclipsed by regulatory unpredictibilty.2

Industry executives noted that the agency sometimes issued rejection letters for therapies that had previously received preliminary support from FDA staff. A high-profile example involved Replimune’s melanoma therapy, which was rejected twice, leading the company to accuse the agency of contradicting its own earlier positions.1 Such inconsistencies have created significant hurdles for drugmakers, investors, and patients who rely on the predictability of the regulatory process.

Furthermore, the agency faced backlash for its handling of vaccine eligibility. According to the AP, Dr. Vinay Prasad, Makary’s deputy, was reported to have at times overruled or clashed with career staff in decisions involving access to new COVID-19 shots and initially declined to consider a new mRNA flu vaccine from Moderna.2 That decision was reversed after Moderna indicated it would challenge the decision and request intervention from the White House, further signaling a breakdown in standard regulatory order.2

What Led to Makary’s Departure?

In recent weeks, Anti-abortion groups criticized the commissioner for allegedly delaying a review of the abortion pill mifepristone.2 Simultaneously, vaping lobbyists successfully pressured the administration after claiming Makary was blocking the approval of fruit-flavored e-cigarettes. The FDA authorized the first of such products last week.2

What Is the Future Outlook for the FDA?

With Makary’s exit, the fate of several fledgling programs remains uncertain. Many of his initiatives to speed up drug reviews have not undergone the formal federal rule-making required to be enshrined in U.S. regulations, leaving them vulnerable to being overturned by his successor.2 The transition to acting leadership under Diamantas may offer a pause in the recent cycle of controversial mandates, but the search for a permanent, Senate-confirmed commissioner suggests that a period of regulatory flux could continue.

References

1. Abutaleb, Y. Makary resigns as FDA commissioner after turmoil. Reuters. Published May 12, 2026. Accessed May 12, 2026. https://www.reuters.com/business/healthcare-pharmaceuticals/fda-commissioner-makary-is-resigning-politico-reports-2026-05-12/
2. Perrone, M, and Min Kim, S. Makary resigns as FDA commissioner amid agency turmoil, sources say. Associated Press. Published May 12, 2026. Accessed May 12, 2026. https://apnews.com/article/fda-trump-makary-kennedy-vaccines-drugs-ef151784342c48cca3b91a829d615b5e